NYSEAMERICAN:INFUInfuSystem Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding InfuSystem Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.87 +1.34 (+10.69 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$12.58Now: $13.87▼$14.1950-Day Range N/A52-Week Range$4.30Now: $13.87▼$14.19Volume296,726 shsAverage Volume101,065 shsMarket Capitalization$278.37 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole mounted and ambulatory infusion pumps; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. InfuSystem Holdings Inc. was founded in 2005 and is headquartered in Madison Heights, Michigan.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingInfuSystem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, InfuSystem has a potential upside of 22.6% from its current price of $13.87.Amount of Analyst CoverageInfuSystem has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesInfuSystem has received 79 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInfuSystem has received 93 “underperform” votes. (Add your “underperform” vote.)Community SentimentInfuSystem has received 54.07% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about InfuSystem and other stocks. Vote “Outperform” if you believe INFU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INFU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInfuSystem does not currently pay a dividend.Dividend GrowthInfuSystem does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InfuSystem insiders have sold 31,264.40% more of their company's stock than they have bought. Specifically, they have bought $19,867.00 in company stock and sold $6,231,165.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.96 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:INFU Previous SymbolNYSE:INFU CUSIPN/A CIK1337013 Webir.infusystem.com Phone+1-248-2911210Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees237 Outstanding Shares20,070,000Market Cap$278.37 million Next Earnings Date8/13/2020 (Confirmed) OptionableNot Optionable $13.87 +1.34 (+10.69 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive INFU News and Ratings via Email Sign-up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter. InfuSystem (NYSEAMERICAN:INFU) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of InfuSystem? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InfuSystem in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InfuSystem. When is InfuSystem's next earnings date? InfuSystem is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for InfuSystem. How can I listen to InfuSystem's earnings call? InfuSystem will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were InfuSystem's earnings last quarter? InfuSystem Holdings Inc (NYSEAMERICAN:INFU) issued its earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.02) EPS for the quarter. The medical instruments supplier earned $21.55 million during the quarter. View InfuSystem's earnings history. What price target have analysts set for INFU? 1 equities research analysts have issued twelve-month price objectives for InfuSystem's stock. Their forecasts range from $17.00 to $17.00. On average, they expect InfuSystem's share price to reach $17.00 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View analysts' price targets for InfuSystem. Has InfuSystem been receiving favorable news coverage? Headlines about INFU stock have been trending very negative this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. InfuSystem earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about InfuSystem. Who are some of InfuSystem's key competitors? Some companies that are related to InfuSystem include Advanced Medical Solutions Group (AMS), Clover (CLV), Retractable Technologies (RVP), CRH Medical (CRH), Bovie Medical (BVX), Tristel (TSTL), CRH Medical (CRHM), CRH Medical (CRHM), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), SDI (SDI), Daxor (DXR), Daxor (DXR), IsoRay (ISR) and IsoRay (ISR). View all competitors. What other stocks do shareholders of InfuSystem own? Based on aggregate information from My MarketBeat watchlists, some companies that other InfuSystem investors own include Macquarie Infrastructure (MIC), Second Sight Medical Products (EYES), NovaBay Pharmaceuticals (NBY), Ampio Pharmaceuticals (AMPE), Otelco (OTEL), Pershing Gold (PGLC), VirnetX (VHC), AgroFresh Solutions (AGFS), Agenus (AGEN) and CBAK Energy Technology (CBAT). Who are InfuSystem's key executives? InfuSystem's management team includes the following people: Mr. Richard A. DiIorio, Pres, CEO & Director (Age 44)Mr. Gregory Schulte, Exec. VP & CFO (Age 52)Mr. Thomas Mark Ruiz, Sr. VP of Sales & MarketingMr. John Haggerty, Sr. VP of Biomedical Services & LogisticsMs. Jean Pfeiffer, Sr. VP of Strategic Initiatives What is InfuSystem's stock symbol? InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU." Who are InfuSystem's major shareholders? InfuSystem's stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (0.31%), Mackay Shields LLC (0.20%), Virtu Financial LLC (0.07%), New York State Common Retirement Fund (0.07%) and Strs Ohio (0.02%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Barry G Steele, Christopher R Sansone, Gregg Owen Lehman, Jeannine Sheehan, Meridian Ohc Partners, Lp, Paul Andrew Gendron, Richard Dilorio, Ronald H Jr Peele, Scott Shuda, Terry L Armstrong and Thomas Mark Ruiz. View institutional ownership trends for InfuSystem. Which major investors are buying InfuSystem stock? INFU stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Mackay Shields LLC, Virtu Financial LLC, New York State Common Retirement Fund, and Strs Ohio. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Barry G Steele, Christopher R Sansone, Jeannine Sheehan, Paul Andrew Gendron, Richard Dilorio, Ronald H Jr Peele, Scott Shuda, and Terry L Armstrong. View insider buying and selling activity for InfuSystem. How do I buy shares of InfuSystem? Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is InfuSystem's stock price today? One share of INFU stock can currently be purchased for approximately $13.87. How big of a company is InfuSystem? InfuSystem has a market capitalization of $278.37 million. InfuSystem employs 237 workers across the globe. What is InfuSystem's official website? The official website for InfuSystem is ir.infusystem.com. How can I contact InfuSystem? InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210. This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
